Literature DB >> 22450533

Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura.

Luca A Lotta, Ilaria Mancini, Giacomo Tuana, Khaled M Musallam, Flora Peyvandi.   

Abstract

Thienopyridines are commonly used anti-platelet drugs that may be associated with the development of secondary, drug-induced thrombotic thrombocytopenic purpura (TTP), a rare but potentially life threatening condition. We report the case of a 70 year-old man with a history of recurrent idiopathic TTP episodes who was treated with clopidogrel and then ticlopidine for thromboprophylaxis after percutaneous coronary intervention. Treatment was successful with no signs of TTP recurrence. Platelet counts and ADAMTS13 activity levels remained normal for months after the initiation of anti-platelet therapy, with no reappearance of anti-ADAMTS13 autoantibodies. This report demonstrates that thienopyridines do not necessarily induce TTP in patients with a history of TTP who are in disease remission.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450533     DOI: 10.1007/s11239-012-0717-7

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  10 in total

Review 1.  Thrombotic microangiopathies.

Authors:  Joel L Moake
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

Review 2.  Clinical practice. Thrombotic thrombocytopenic purpura.

Authors:  James N George
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

Review 3.  Bedside evaluation of thienopyridine antiplatelet therapy.

Authors:  Matthew J Price
Journal:  Circulation       Date:  2009-05-19       Impact factor: 29.690

4.  Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission.

Authors:  L A Lotta; R Lombardi; M Mariani; S Lancellotti; R De Cristofaro; M J Hollestelle; M T Canciani; P M Mannucci; F Peyvandi
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

5.  Clopidogrel (Plavix) desensitization: a case series.

Authors:  Miguel G Camara; Francis Q Almeda
Journal:  Catheter Cardiovasc Interv       Date:  2005-08       Impact factor: 2.692

6.  Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; L Rice; R Sarode; T W Chow; J L Moake
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

7.  Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Mariagabriella Mariani; Dario Consonni; Ilaria Mancini; Roberta Palla; Alberto Maino; Dragica Vucelic; Michele Pizzuti; Pier M Mannucci; Flora Peyvandi
Journal:  Br J Haematol       Date:  2010-10-19       Impact factor: 6.998

Review 8.  Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).

Authors:  Anaadriana Zakarija; Hau C Kwaan; Joel L Moake; Nicholas Bandarenko; Dilip K Pandey; June M McKoy; Paul R Yarnold; Dennis W Raisch; Jeffrey L Winters; Thomas J Raife; John F Cursio; Thanh Ha Luu; Elizabeth A Richey; Matthew J Fisher; Thomas L Ortel; Martin S Tallman; X Long Zheng; Masanori Matsumoto; Yoshihiro Fujimura; Charles L Bennett
Journal:  Kidney Int Suppl       Date:  2009-02       Impact factor: 10.545

Review 9.  Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.

Authors:  J Evan Sadler
Journal:  Blood       Date:  2008-07-01       Impact factor: 22.113

10.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

  10 in total
  2 in total

Review 1.  Paradoxical thrombosis, part 2: anticoagulant and antiplatelet therapy.

Authors:  Giuseppe Lippi; Emmanuel J Favaloro; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  ST-segment elevation myocardial infarction treated with thrombolytic therapy in a patient with thrombotic thrombocytopenic purpura.

Authors:  Jacob A Doll; Jacob P Kelly
Journal:  J Thromb Thrombolysis       Date:  2014-07       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.